429 related articles for article (PubMed ID: 20049846)
21. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.
Goel RK; Lukong KE
Cancer Metastasis Rev; 2016 Jun; 35(2):179-99. PubMed ID: 27067725
[TBL] [Abstract][Full Text] [Related]
22. The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets.
Liu W; Kovacevic Z; Peng Z; Jin R; Wang P; Yue F; Zheng M; Huang ML; Jansson PJ; Richardson V; Kalinowski DS; Lane DJ; Merlot AM; Sahni S; Richardson DR
Oncotarget; 2015 Nov; 6(34):35522-41. PubMed ID: 26431493
[TBL] [Abstract][Full Text] [Related]
23. Cellular and molecular mechanisms of cancer cell invasion.
De Wever O; Lapeire L; De Boeck A; Hendrix A
Verh K Acad Geneeskd Belg; 2010; 72(5-6):309-26. PubMed ID: 21409955
[TBL] [Abstract][Full Text] [Related]
24. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of targeted interference with Src-mediated signal transduction events.
Ly QP; Yeatman TJ
Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
[No Abstract] [Full Text] [Related]
27. Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis.
Kang NJ; Shin SH; Lee HJ; Lee KW
Pharmacol Ther; 2011 Jun; 130(3):310-24. PubMed ID: 21356239
[TBL] [Abstract][Full Text] [Related]
28. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
Elsberger B
Crit Rev Oncol Hematol; 2014 Mar; 89(3):343-51. PubMed ID: 24388104
[TBL] [Abstract][Full Text] [Related]
29. A Jnk-Rho-Actin remodeling positive feedback network directs Src-driven invasion.
Rudrapatna VA; Bangi E; Cagan RL
Oncogene; 2014 May; 33(21):2801-6. PubMed ID: 23831567
[TBL] [Abstract][Full Text] [Related]
30. Src inhibitors in lung cancer: current status and future directions.
Rothschild SI; Gautschi O; Haura EB; Johnson FM
Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
[TBL] [Abstract][Full Text] [Related]
31. Src signaling pathways in prostate cancer.
Varkaris A; Katsiampoura AD; Araujo JC; Gallick GE; Corn PG
Cancer Metastasis Rev; 2014 Sep; 33(2-3):595-606. PubMed ID: 24522479
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of Src expression and activity in human neoplasia.
Chatzizacharias NA; Kouraklis GP; Giaginis CT; Theocharis SE
Histol Histopathol; 2012 Jun; 27(6):677-92. PubMed ID: 22473690
[TBL] [Abstract][Full Text] [Related]
33. Src family kinases in tumor progression and metastasis.
Summy JM; Gallick GE
Cancer Metastasis Rev; 2003 Dec; 22(4):337-58. PubMed ID: 12884910
[TBL] [Abstract][Full Text] [Related]
34. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
Benati D; Baldari CT
Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
[TBL] [Abstract][Full Text] [Related]
35. Src kinase inhibitors: promising cancer therapeutics?
Creedon H; Brunton VG
Crit Rev Oncog; 2012; 17(2):145-59. PubMed ID: 22471705
[TBL] [Abstract][Full Text] [Related]
36. NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways.
Honda A; Kuramoto K; Niwa T; Naito H
Blood Cancer J; 2018 Jun; 8(7):62. PubMed ID: 29941953
[No Abstract] [Full Text] [Related]
37. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Zhang S; Yu D
Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of perylenediimide derivatives for potential therapeutic benefits on cancer chemotherapy.
Keskin T; Isgor BS; Isgor YG; Yukruk F
Chem Biol Drug Des; 2012 Nov; 80(5):675-81. PubMed ID: 22834711
[TBL] [Abstract][Full Text] [Related]
39. Novel patented SRC kinase inhibitor.
Lu XL; Liu XY; Cao X; Jiao BH
Curr Med Chem; 2012; 19(12):1821-9. PubMed ID: 22414081
[TBL] [Abstract][Full Text] [Related]
40. Contribution of phosphoproteomics in understanding SRC signaling in normal and tumor cells.
Sirvent A; Urbach S; Roche S
Proteomics; 2015 Jan; 15(2-3):232-44. PubMed ID: 25403792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
